Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma
EV-302/KEYNOTE-A39 泛亚洲亚组分析:一项评估恩福妥单抗和帕博利珠单抗治疗未经治疗的晚期尿路上皮癌患者的 3 期研究
期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-025-02950-8
Kikuchi, Eiji; Van der Heijden, Michiel S; Valderrama, Begoña P; Gupta, Shilpa; Bedke, Jens; Shin, Sang Joon; Li, Jian-Ri; Guo, Jun; Danchaivijitr, Pongwut; Kanesvaran, Ravindran; Park, Se Hoon; Su, Wen-Pin; Kandori, Shuya; Bae, Woo Kyun; Wong, Alvin; Gorla, Seema; Bavle, Abhishek; Yu, Xuesong; Lu, Yi-Tsung; Powles, Thomas